IBIO iBio Forecast, Technical & Fundamental Analysis
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies... Show more
IBIO is expected to report earnings to fall 8.86% to -6 cents per share on September 29
Q2'26
Est.
$-0.06
Q1'26
Beat
by $0.13
Q4'25
Beat
by $0.34
Q3'25
Beat
by $0.14
Q2'25
Missed
by $0.12
The last earnings report on May 12 showed earnings per share of -7 cents, beating the estimate of -20 cents. With 68.50K shares outstanding, the current market capitalization sits at 69.55M.
A.I. Advisor
published General Information
General Information
a company which engages in the development and commercialization of vaccines and therapeutic proteins
A.I.dvisor indicates that over the last year, IBIO has been loosely correlated with WVE. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if IBIO jumps, then WVE could also see price increases.
IBIO sees its Stochastic Oscillator climbs out of oversold territory
On July 22, 2026, the Stochastic Oscillator for IBIO moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 62 instances where the indicator left the oversold zone. In of the 62 cases the stock moved higher in the following days. This puts the odds of a move higher at over .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IBIO's RSI Oscillator exited the oversold zone, of 43 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on July 30, 2026. You may want to consider a long position or call options on IBIO as a result. In of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for IBIO just turned positive on July 27, 2026. Looking at past instances where IBIO's MACD turned positive, the stock continued to rise in of 39 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IBIO advanced for three days, in of 223 cases, the price rose further within the following month. The odds of a continued upward trend are .
IBIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
IBIO moved below its 50-day moving average on July 02, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for IBIO moved below the 200-day moving average on June 25, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBIO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.897) is normal, around the industry mean (19.620). P/E Ratio (0.654) is within average values for comparable stocks, (38.277). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.532). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (333.333) is also within normal values, averaging (420.906).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IBIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
